logo

For the Inventor, By the Inventor

Yarnton, United Kingdom

Mary F Fitzgerald

This inventor holds 18 USPTO granted patents and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Bayer Aktiengesellschaft, Bayer Healthcare Aktiengesellschaft, Bayer Pharma Aktiengesellschaft. Active years: 1996-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mary F Fitzgerald. Retrieved from https://idiyas.com/inventor/mary-f-fitzgerald

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18

% Patents Active = 27.8


Average Co-Inventor Count = 10.4

ph-index = 6

Forward Citations = 84(Granted Patents)


Location History:

  • Begbroke, GB (1996 - 1997)
  • Begbroke Oxford, GB (2002 - 2004)
  • Oxon, GB (2005)
  • Yarton, GB (2006)
  • Yarnton, Oxfordshire, GB (2006)
  • Oxfordshire, GB (2006)
  • Oxford, GB (2007 - 2010)
  • Yarnton, GB (2001 - 2012)

Company Filing History:

goldMedal10 out of 12,268 
 
Bayer Aktiengesellschaft
 patents
silverMedal5 out of 77 
 
Bayer Healthcare Aktiengesellschaft
 patents
bronzeMedal1 out of 387 
 
Bayer Pharma Aktiengesellschaft
 patents
4. 1 out of 192 
 
Bayer Schering Pharma Ag
 patents
5. 1 out of 834,570 
Other
 patents

Years Active: 1996-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Dihydropyridine Derivatives
Neutrophil Elastase Inhibitors
Pyrimidinone Derivatives
Therapeutic Agents
Inflammatory Processes
Matrix Metalloprotease Inhibitors
Benzofuranyl Derivatives
Imidazopyridinones
Heterocycles
Acute Inflammation
Chronic Inflammation
Ischaemic Processes
18 patents (USPTO):Explore Patents
1. 8173665 - I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use (2012-05-08),
2. 7691854 - Dihydropyridine derivatives for use as human neutrophil elastase inhibitors (2010-04-06),
3. 7687510 - Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes (2010-03-30),
4. 7566723 - 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use (2009-07-28),
5. 7230017 - Dihydropyridinone derivatives (2007-06-12),
6. 7199136 - 1,4-dihydro-1,4-diphenylpyridine derivatives (2007-04-03),
7. 7115602 - Heterocycles 3 (2006-10-03),
8. 7087605 - 5-Ethyl-imidazotriazinones (2006-08-08),
9. 7074790 - 5-ethylimidarotriazones (2006-07-11),
10. 6984646 - Imidazopyridinones as p38 map kinase inhibitors (2006-01-10),
11. 6900194 - Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors for the treatment of respiratory diseases (2005-05-31),
12. 6677372 - N-(3-benzofuranyl)urea-derivatives (2004-01-13),
13. 6610687 - Benzofuranylsulfonates (2003-08-26),
14. 6399657 - N-(3-benzofuranyl) urea-derivatives (2002-06-04),
15. 6169092 - 3-Ureido-pyridofurans and -pyridothiophenes for the treatment of inflammatory processes (2001-01-02),

Title: Mary F Fitzgerald: Pioneering Innovator in Pharmaceutical Sciences

Introduction:

Mary F Fitzgerald, a prolific inventor based in Yarnton, GB, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 18 patents, her groundbreaking inventions have focused on developing novel compounds for various medical applications.

Latest Patents:

1. "I-phenyl 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use": This patent revolves around 4-cyanophenyl, 2-sulfanyl, 1-phenyl pyrimidine derivatives, essential in treating chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.

2. "Dihydropyridine derivatives for use as human neutrophil elastase inhibitors": Fitzgerald's innovative dihydropyridine derivatives have paved the way for medicaments treating chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction, and heart failure development.

Career Highlights:

Mary F Fitzgerald has honed her craft at renowned companies such as Bayer Aktiengesellschaft and Bayer Healthcare Aktiengesellschaft. Her expertise and dedication to advancing pharmaceutical research have led to groundbreaking discoveries in the industry, revolutionizing treatment options for various critical conditions.

Collaborations:

Throughout her illustrious career, Mary F Fitzgerald has collaborated with esteemed professionals in the field, including Karl-Heinz Schlemmer and Graham Sturton. Together, they have synergized their efforts to push the boundaries of pharmaceutical innovation, fostering a culture of excellence and creativity.

Conclusion:

In conclusion, Mary F Fitzgerald stands out as a trailblazing inventor whose relentless pursuit of scientific excellence has revolutionized the pharmaceutical landscape. Her remarkable patents and collaborative spirit underscore her as a pioneering figure in the field of pharmaceutical sciences, shaping the future of healthcare and improving countless lives worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…